MyChesCo on MSN1 天
AstraZeneca Showcases TAGRISSO’s Potential in EGFR-Mutated Lung Cancer at ELCC 2025
AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...
Medscape1 天
Osimertinib OS Benefit Persists Among Patients With EGFR+ NSCLC
OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...
Pharmaceutical Technology on MSN12 小时
Apollomics and LaunXP agree on NSCLC treatment in Asia
Apollomics and LaunXP have signed an agreement to develop and commercialise the former’s c-Met inhibitor vebreltinib combined ...
PharmExec1 天
Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate ...
Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% ...
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in ...
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a ...
Science Daily12 天
Vaccine may improve breast cancer treatment outcomes
Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...
European Medical Journal1 天
Immunotherapy Boosts Chemotherapy Efficacy in Early-Stage Breast Cancer
Adding nivolumab to neoadjuvant chemotherapy significantly improves response rates in high-risk early-stage ER+/HER2− breast ...
HealthDay on MSN6 天
Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection
For patients with resected stage IB-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer, molecular ...